MedTrace Logo

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

NCT01192230 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-09-16

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy and safety of endostatin combined with Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or second-line chemotherapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Endostatins

7.5mg/m2 qd \*14d,q3w

DRUG

Docetaxel

75mg/m2 D1, q3w,4-6cycles

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jianhua Chang, MD,PhD · Fudan University affiliated cancer hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192230 on ClinicalTrials.gov